SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

L-168,049

Item No. 41112

CAS Registry No.:	191034-25-0
Formal Name:	4-[3-(5-bromo-2-propoxyphenyl)-5-(4-chlorophenyl)-1H-pyrrol-2-yl]-pyridine
Synonyms:	GCGR Antagonist II, Glucagon Receptor Antagonist II,
MF:	$C_{24}H_{20}BrClN_2O$
FW:	467.8
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

L-168,049 is supplied as a solid. A stock solution may be made by dissolving the L-168,049 in the solvent of choice, which should be purged with an inert gas. L-168,049 is soluble (≥10 mg/ml) in ethanol and DMSO.

Description

L-168,049 is a glucagon receptor (GCGR) antagonist (IC_{50}s = 3.7 and 179 nM in the absence and presence of $MgCl_2$, respectively).[1] It prevents glucagon-induced increases in IL-1β and IL-6 levels in, and levels secreted from, HepG2 cells when used at a concentration of 3.7 nM.[2] L-168,049 inhibits glucagon-induced increases in the mRNA encoding complement 3 (C3), C-reactive protein (CRP), and fibrinogen in HepG2 cells. *In vivo*, L-168,049 (1 µM in drinking water) inhibits glucagon-induced increases in the hepatic levels of NOD-like receptor protein 3 (NLRP3), phosphorylated NF-κB, and phosphorylated Stat3 in mice.

References

1. Cascieri, M.A., Koch, G.E., Ber, E., *et al.* Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. *J. Biol. Chem.* **274(13)**, 8694-8697 (1999).
2. Andreozzi , F., Di Fatta, C., Spiga, R., *et al.* Glucagon induces the hepatic expression of inflammatory markers in vitro and in vivo. *Diabetes Obes. Metab.* **25(2)**, 556-569 (2023).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM